In the latest session, Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $5.63 up 4.26% from its previous closing price of $5.40. In other words, the price has increased by $+0.23 from its previous closing price. On the day, 1711850 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Allogene Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.58 and its Current Ratio is at 12.58. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.15.
On December 08, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $7.Citigroup initiated its Buy rating on December 08, 2023, with a $7 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 30 ’24 when Parker Geoffrey M. bought 190 shares for $3.60 per share. The transaction valued at 683 led to the insider holds 819,590 shares of the business.
MESSEMER DEBORAH M. sold 18,640 shares of ALLO for $50,317 on Dec 18 ’23. The Director now owns 62,456 shares after completing the transaction at $2.70 per share. On Aug 07 ’23, another insider, Mayo Stephen, who serves as the Director of the company, sold 10,000 shares for $4.29 each. As a result, the insider received 42,855 and left with 25,328 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 946.56M and an Enterprise Value of 571.15M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4986.40 while its Price-to-Book (P/B) ratio in mrq is 1.62. Its current Enterprise Value per Revenue stands at 3.07k whereas that against EBITDA is -1.76.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $6.89, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is 3.87, while the 200-Day Moving Average is calculated to be 3.95.
Shares Statistics:
For the past three months, ALLO has traded an average of 3.07M shares per day and 2.23M over the past ten days. A total of 144.44M shares are outstanding, with a floating share count of 103.86M. Insiders hold about 38.28% of the company’s shares, while institutions hold 61.13% stake in the company. Shares short for ALLO as of Feb 15, 2024 were 23.45M with a Short Ratio of 7.65, compared to 30.21M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.93% and a Short% of Float of 20.51%.
Earnings Estimates
There are 16 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.45 for the current quarter, with a high estimate of -$0.34 and a low estimate of -$0.62, while EPS last year was -$0.66. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.33 and low estimates of -$0.64.
Analysts are recommending an EPS of between -$1.89 and -$2.18 for the fiscal current year, implying an average EPS of -$2.01. EPS for the following year is -$1.76, with 17 analysts recommending between -$1.36 and -$2.4.
